Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AMKOR TECHNOLOGY, INC.AMKR · Entity 3481 | Director | September 22, 2026 | September 24, 2026 |
| Baudax Bio, Inc.BXRX · Entity 109081 | Director | June 15, 2022 | June 17, 2022 |
| Lifeward Ltd.RWLK · Entity 7620 | 10% owner | June 26, 2017 | June 28, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AMKOR TECHNOLOGY, INC.
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,619.5144 |
Reported balance
After 2026-09-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-22 · Grant · Acquired 3.9978 · Balance 2,619.5144 F1: Represents dividend equivalent units ("DEUs") accrued upon the payment of a dividend on September 22, 2026 with respect to time-vested restricted stock units ("RSUs") of Amkor Technology, Inc. (the "Issuer") granted to the Reporting Person on May 13, 2026. Each DEU represents an additional RSU subject to the same provisions as the RSU with respect to which the DEU was accrued. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents dividend equivalent units ("DEUs") accrued upon the payment of a dividend on September 22, 2026 with respect to time-vested restricted stock units ("RSUs") of Amkor Technology, Inc. (the "Issuer") granted to the Reporting Person on May 13, 2026. Each DEU represents an additional RSU subject to the same provisions as the RSU with respect to which the DEU was accrued.
Baudax Bio, Inc.
Report date June 15, 2022 · Filed June 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,820 |
Reported balance
After 2022-06-15 transaction · row 1
1 source rowRow 1 · 2022-06-15 · Grant · Acquired 39,473 · Balance 46,820 F1: Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") is the economic equivalent of one share of Baudax Bio, Inc. (the "Company") common stock, and may be settled, at the Company's option, in cash, shares of common stock, or a combination thereof. The RSUs vest in full on June 15, 2023, subject to continued service with the Company through the vesting date. Upon vesting, if settled in cash, each RSU will entitle the grantee to a cash-payment equal to the "Fair Market Value" (as defined in the Company's 2019 Equity Incentive Plan) of one share of the Company's common stock on the vesting date.
Lifeward Ltd.
Report date June 26, 2017 · Filed June 28, 2017
Jointly reported with SCP Vitalife Partners (Israel) II, L.P., SCP Vitalife II Associates, L.P., SCP Vitalife II GP, Ltd., LUDOMIRSKI ABRAHAM
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value NIS 0.01 per shareSEC Table I · non-derivative | Direct | 339,900 |
Last balance in matching sequence
After 2017-06-27 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-26 · Sale · Disposed 9,271 · Balance 352,411 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016. F2: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest. Row 2 · 2017-06-27 · Sale · Disposed 12,511 · Balance 339,900 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.2000, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. F2: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted December 15, 2016.
F2: The Ordinary Shares are directly held by SCP Vitalife Partners (Israel) II, L.P. ("SCP Vitalife") and indirectly held by SCP Vitalife II Associates, L.P. ("SCP Vitalife Associates"), the sole general partner of SCP Vitalife, SCP Vitalife II, GP, Ltd. ("SCP Vitalife GP"), the sole general partner of SCP Vitalife Associates, and the individual directors of SCP Vitalife GP (SCP Vitalife Associates, SCP Vitalife GP and the individual directors of SCP Vitalife GP together, the "SCP Vitalife Indirect Reporting Persons"). The individual directors of SCP Vitalife GP are Jeffrey Dykan, Winston J. Churchill, Abraham Ludomirski and Wayne B. Weisman. The SCP Vitalife Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the SCP Vitalife Ordinary Shares in which the SCP Vitalife Indirect Reporting Persons have no pecuniary interest.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.0000 to $3.2000, inclusive. The reporting person undertakes to provide to ReWalk Robotics, Ltd. ("ReWalk"), any security holder of ReWalk, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INNOVATIVE SOLUTIONS & SUPPORT INC
Report date June 13, 2023 · Filed June 14, 2023
Section 16 reporting ended · disclosed 2023-06-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,523 |
Reported balance
After 2023-06-13 transaction · row 1
1 source rowRow 1 · 2023-06-13 · Sale · Disposed 3,499 · Balance 9,523 |
Societal CDMO, Inc.
Report date April 08, 2024 · Filed April 09, 2024
Section 16 reporting ended · disclosed 2024-04-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-04-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-04-08 · Other · Disposed 227,982 · Balance 73,620 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest. Row 2 · 2024-04-08 · Disposition to issuer · Disposed 73,620 · Balance 0 F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 | Direct | 0 |
Reported balance
After 2024-04-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-04-08 · Disposition to issuer · Disposed 118,182 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 | Direct | 0 |
Reported balance
After 2024-04-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-04-08 · Disposition to issuer · Disposed 27,229 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of February 28, 2024, by and among the Issuer, CoreRx, Inc., a Florida corporation ("Parent") and Cane Merger Sub, Inc., a Pennsylvania corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of April 8, 2024 (the "Effective Time") with the Issuer surviving the merger. At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $1.10 per Share in cash (the "Offer Amount"), subject to any applicable withholding taxes and without interest.
F2: Represents restricted stock units granted under an Issuer equity plan ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one Share upon vesting of the RSU. Pursuant to the terms of the Merger Agreement, each outstanding RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each RSU then outstanding was cancelled and converted into a cash payment equal to the product of (A) the total number of Shares then underlying such RSU multiplied by (B) the Offer Amount, without interest and subject to any withholding of taxes.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding and unvested option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") vested in full. At the Effective Time, each Issuer Stock Option with an exercise price that is less than the Offer Amount was cancelled and converted into the right to receive a cash payment equal to the product of (A) the excess, if any, of the Offer Amount over the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | Exercise / conversion(Director Stock Option (Right to Buy) · Derivative | 10,000 | $10.97 Strike: $10.97 | $109,700.00 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · derivative · entry 12 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Amkor Technology, Inc. · 10,000 shares Expires 2017-08-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 20,000 | $7.71 Strike: $7.71 | $154,200.00 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · derivative · entry 11 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Amkor Technology, Inc. · 20,000 shares Expires 2020-05-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | SaleAmkor Technology, Inc. Common Stock | 16,598 | $11.99 | $199,010.02 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · nonDerivative · entry 6 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,776 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from 11.90 to 12.02. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | Exercise / conversionAmkor Technology, Inc. Common Stock | 16,598 | $6.46 | $107,223.08 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · nonDerivative · entry 5 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,374 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | SaleAmkor Technology, Inc. Common Stock | 10,000 | $11.99 | $119,900.00 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · nonDerivative · entry 4 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,776 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from 11.90 to 12.02. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | Exercise / conversionAmkor Technology, Inc. Common Stock | 10,000 | $10.97 | $109,700.00 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · nonDerivative · entry 3 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | SaleAmkor Technology, Inc. Common Stock | 20,000 | $11.99 | $239,800.00 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · nonDerivative · entry 2 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,776 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from 11.90 to 12.02. Read SEC document |
| May 11, 2017 Filed May 15, 2017 23:14 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | Exercise / conversionAmkor Technology, Inc. Common Stock | 20,000 | $7.71 | $154,200.00 |
DisclosureSEC source: 0001209191-17-032491 · doc4.xml · nonDerivative · entry 1 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2017 Filed May 4, 2017 22:48 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | GrantDirector Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0001209191-17-030135 · doc4.xml · derivative · entry 2 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Amkor Technology, Inc. Common Stock · 20,000 shares Expires 2027-05-02 F2 · derivative.exercise_date: These options vest 100% on the earlier of the first anniversary of the grant date, or the date of the first annual meeting of stockholders following the grant date. Read SEC document |
| May 02, 2017 Filed May 4, 2017 22:48 UTC | AMKOR TECHNOLOGY, INC. AMKR · Entity 3481 | GrantCommon Stock | 3,415 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-030135 · doc4.xml · nonDerivative · entry 1 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,776 F1 · shares: These are restricted shares which vest 100% on the earlier of the first anniversary of the grant date, or the date of the first annual meeting of stockholders following the grant date. Read SEC document |
| January 02, 2017 Filed Jan 3, 2017 21:21 UTC | INNOVATIVE SOLUTIONS & SUPPORT INC ISSC · Entity 544 | Exercise / conversionRestricted Stock Units · Derivative | 14,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-000068 · edgar.xml · derivative · entry 3 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,234 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represented a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on November 12, 2015 as compensation for service on the Issuer's board of directors during the year ended December 31, 2016 and vested in full on January 2, 2017. F2 · derivative.expiration_date: The restricted stock units were granted on November 12, 2015 as compensation for service on the Issuer's board of directors during the year ended December 31, 2016 and vested in full on January 2, 2017. Read SEC document |
| January 02, 2017 Filed Jan 3, 2017 21:21 UTC | INNOVATIVE SOLUTIONS & SUPPORT INC ISSC · Entity 544 | Exercise / conversionCommon Stock | 14,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-000068 · edgar.xml · nonDerivative · entry 1 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represented a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 12, 2015 Filed Oct 3, 2016 20:21 UTC | INNOVATIVE SOLUTIONS & SUPPORT INC ISSC · Entity 544 | GrantRestricted Stock Units · Derivative | 14,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030184 · edgar.xml · derivative · entry 1 CHURCHILL WINSTON J · CIK 0000923792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,234 Underlying: Common Stock · 14,234 shares Expires not disclosed F1 · security: Stock-based compensation for the year ending December 31, 2016. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units will vest in full on January 2, 2017, provided that if the Reporting Person resigns from the Issuer's board of directors prior to January 1, 2017 he will receive a pro rated number of shares based on the number of days served as a director during 2016. F3 · derivative.expiration_date: The restricted stock units will vest in full on January 2, 2017, provided that if the Reporting Person resigns from the Issuer's board of directors prior to January 1, 2017 he will receive a pro rated number of shares based on the number of days served as a director during 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.